GoStork Launches Online Platform to Simplify Search for Surrogacy Agencies and Egg Donors
March 02, 2020 09:05 ET
|
gostork.com
NEW YORK, NY , March 02, 2020 (GLOBE NEWSWIRE) -- GoStork, a New York City-based technology company, has announced the launch of an online platform that helps intended parents find, compare, and...
Business Capital Delivers Financing for Bay Area Medical Clinic
February 12, 2020 05:00 ET
|
Business Capital
SAN FRANCISCO, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Business Capital structured and delivered approximately $6MM in senior secured loans for NOVA IVF, a clinic established in 1987, providing in vitro...
ObsEva and Yuyuan BioScience Technology Announce Sublicense Agreement to Develop and Commercialize Nolasiban in the People's Republic of China
January 13, 2020 01:00 ET
|
ObsEva SA
Geneva, Switzerland, 13 January 2020 – ObsEva and Yuyuan BioScience Technology (“Yuyuan”) today announced that they have entered into a sublicense agreement to develop and commercialize nolasiban...
Hamilton Thorne to Present at the 2019 Canaccord Genuity Health and Wellness Investor Day
October 31, 2019 08:30 ET
|
Hamilton Thorne Ltd.
BEVERLY, Mass. and TORONTO, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX-V: HTL), a leading provider of precision instruments, consumables, software and services to the Assisted...
ObsEva Announces Clearance to Initiate Pivotal US Phase 3 Clinical Trial (IMPLANT 3) of Nolasiban in Women Undergoing Embryo Transfer Following IVF
October 31, 2019 02:00 ET
|
ObsEva SA
FDA Allows IMPLANT 3 Trial to Begin Geneva, Switzerland and Boston, MA – October 31, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the...
ObsEva Reports New Clinical Evidence of Nolasiban Mechanism of Action, Supporting Its Potential to Increase Live Birth Rate Following Embryo Transfer in IVF
September 03, 2019 01:00 ET
|
ObsEva SA
Results show decreased uterine contractions, increased endometrial blood flow and gene expression relevant for uterine receptivity to implantation 4Q:19 Read-out confirmed for Phase 3 IMPLANT 4 trial...
ObsEva Hosts KOL Meeting on IVF Trends, Unmet Need and Market Potential of Nolasiban
July 17, 2019 12:00 ET
|
ObsEva SA
Company remains on track to submit Nolasiban MAA in the fourth quarter of 2019 GENEVA, Switzerland and BOSTON, MA - July 17, 2019 – ObsEva SA (NASDAQ:...
ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) July 17, 2019 in New York City
July 12, 2019 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – July 12, 2019– ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for...
Study: IVF Pregnancy Rates Soar after Massage
July 09, 2019 08:00 ET
|
Clear Passage Therapies
Gainesville, FL, July 09, 2019 (GLOBE NEWSWIRE) -- Researchers and physicians were surprised that IVF pregnancy rates increased three to five times the U.S. norm in women over 40 when they...
ObsEva Progressing Toward U.S. Phase 3 Trial for Nolasiban in IVF Following Recent FDA Meeting
June 19, 2019 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – June 19, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...